Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1

Status

Completed 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Lymphoid 3Genitourinary 3Plasma cell 2Other hematologic neoplasm 2Tumor-Agnostic 1Gynecologic 1CNS 1

Conditions

Breast Neoplasms 4

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Lenograstim × Breast × Clear all
NCT05296317 2026-02-19

EMEG-ECDD

Centre Georges Francois Leclerc

Phase NA Completed
97 enrolled
Breast

Breast Neoplasms

NCT00615602 2015-03-04

Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

Hellenic Oncology Research Group

Phase 3 Completed
489 enrolled
Breast

Breast Neoplasms

NCT01985724 2014-05-14

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

Hellenic Oncology Research Group

Phase 3 Completed
650 enrolled
Breast

Breast Neoplasms

NCT00431080 2008-01-21

Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer

Hellenic Oncology Research Group

Phase 3 Completed
478 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡